RenovoRx Gains Traction with Key Cancer Center Adoptions
Event summary
- RenovoRx has expanded commercial adoption of its RenovoCath device to nine active cancer centers, up from five in September 2025.
- City of Hope Cancer Center and Moffitt Cancer Center are the latest additions, demonstrating growing market interest.
- The company generated approximately $900,000 in RenovoCath sales revenue through September 2025.
- RenovoRx has established a dedicated commercial team, including sales and marketing personnel, to drive adoption and revenue growth.
- The company is currently enrolling patients in a Phase III TIGeR-PaC trial evaluating its drug-device combination for locally advanced pancreatic cancer.
The big picture
RenovoRx’s expansion into prominent cancer centers like City of Hope and Moffitt signals a potential shift towards more localized, targeted chemotherapy delivery, a trend driven by the desire to minimize systemic side effects and improve patient outcomes. While the $900,000 in revenue demonstrates early traction, the company’s success hinges on scaling its commercial operations and demonstrating clinical efficacy in the ongoing Phase III trial. The company's focus on targeted therapies aligns with the broader oncology market's move away from traditional, systemic chemotherapy approaches.
What we're watching
- Commercial Execution
- The ability of RenovoRx’s new commercial team to sustain the accelerating adoption rate observed since late 2025 will be critical for achieving revenue growth targets in 2026.
- Trial Outcomes
- The results of the TIGeR-PaC Phase III trial will significantly influence the long-term commercial viability of RenovoRx’s drug-device combination and potential for regulatory approval.
- Reimbursement
- Securing favorable insurance reimbursement for RenovoCath and its combination therapies will be essential for broader adoption and sustained revenue generation.
Related topics